JNJ - Johnson & Johnson Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

JNJ

JOHNSON & JOHNSON

NYSE

$266.32

▲ UP 0.28% (0.74)

KEY STATISTICS

Market Cap$640.02 B

52w High$281.07

52w Low$173.33

Dividend Yield2.11%

FrequencyQuarterly

P/E24.82

Volume4.66M

Shares Out.2.41B

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Joaquin Duato

COMPENSATION 2026

Salary$1,600,000

Stock Awards$15,028,948

Incentive Plan Pay$4,298,700

All Other Comp.$601,231

Total$32,758,111

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 2, 1962

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

141,700

PRICE TARGET

Target High$320.00

Target Low$255.00

Target Median$284.50

Target Consensus$286.93

UPCOMING EARNINGS

DateOct 13, 2026

DayTuesday

Rev. Est.$25.33B

OCT

TUE

SPLIT RECORD

DATE	TYPE	RATIO
2001-06-13	Forward	2:1
1996-06-12	Forward	2:1
1992-06-10	Forward	2:1
1989-05-11	Forward	2:1
1981-05-19	Forward	3:1
1970-05-18	Forward	3:1
1967-06-19	Forward	3:1

PRICE

$266.32 ▲ UP 0.28% (+$0.74)

OVERLAYS

About Johnson & Johnson

https://www.jnj.com ↗

Johnson & Johnson, now focused on innovative medicines and medical devices after spinning off its consumer health brands into Kenvue in 2023, develops and sells healthcare products worldwide to advance human health.

INDUSTRY

Drug Manufacturers - General

A PRODUCT JOHNSON & JOHNSON IS KNOWN FOR

Darzalex (daratumumab)

Darzalex, Johnson & Johnson’s top-selling blood cancer medication, generated $11.7 billion in 2024, marking significant growth and solidifying its role as a key product in the company's oncology portfolio.